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Background: FTY720 (fingolimod, Gilenya™), a structural analog of sphingosine-1-phosphate (S1P), is the first oral
drug approved for treatment the relapsing-remitting form of multiple sclerosis (MS), and its efficacy has been
related to induced lymphopenia and consequent immunosuppression via modulation of S1P1 receptors (S1P1R).
However, due to its lipophilic nature, FTY720 crosses the blood brain barrier (BBB) and could act directly on neural
cells. In this study, we investigated the effectiveness of FTY720 as a neuroprotective agent using in vitro and in vivo
models of excitotoxic neuronal death and examined if FTY720 exerts a direct action on neurons, or/and an indirect
modulation of inflammation-mediated neurodegeneration as a possible mechanism of neuroprotection.
Methods: Primary neuronal and organotypic cortical cultures were treated with N-methyl-D-aspartic acid (NMDA)
to induce excitotoxic cell death (measured by lactate dehydrogenase (LDH) assay or propidium iodide uptake,
respectively). The effects of FTY720 treatment (10, 100 and 1,000 nM) on neuronal survival were examined. As an
in vivo model of neuronal death and inflammation, we used intracerebroventricular (icv) administration of kainic
acid (KA; 0.5 μg/2 μl) in Sprague–Dawley rats. FTY720 was applied icv (1 μg/2 μl), together with KA, plus
intraperitoneally (ip; 1 mg/kg) 24 h before, and daily, until sacrifice 3 days after icv. Rats were evaluated for
neurological score, neuronal loss in CA3 hippocampal region and activation of microglia at the lesion site. In
addition, we tested FTY720 as a modulator of microglia responses using microglial cell cultures activated with
lipopolysaccharide (LPS) and its effects in stress signalling pathways using western blotting for p38 and JNK1/2
mitogen-activated protein kinases (MAPKs).
Results: FTY720 was able to reduce excitotoxic neuronal death in vitro. Moreover, in vivo repeated FTY720
administration attenuated KA-induced neurodegeneration and microgliosis at the CA3 lesion site. Furthermore,
FTY720 negatively modulates p38 MAPK in LPS-activated microglia, whereas it had no effect on JNK1/2 activation.
Conclusions: These data support a role for FTY720 as a neuroprotective agent against excitotoxin-induced
neuronal death and as a negative modulator of neuroinflammation by targeting the p38 MAPK stress signalling
pathway in microglia.
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FTY720 (fingolimod, Gilenya™) is an immunomodulatory
drug approved in 2010 as the first oral treatment for re-
lapsing-remitting multiple sclerosis (MS) [1,2]. The bio-
active form, FTY720-phosphate (FTY720-P), derived from* Correspondence: carlos.matute@ehu.es
1Centro de Investigaciones Biomédicas en Red (CIBERNED), Achucarro
Basque Center for Neuroscience Bizkaia Science and Technology Park,
Building 205, E-48170 Zamudio, Spain
2Departamento de Neurociencias, Universidad del País Vasco, Barrio Sarriena
s/n, E-48940 Leioa, Spain
Full list of author information is available at the end of the article
© 2015 Cipriani et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.the phosphorylation by sphingosine kinase 2 (SphK2), is a
structural analogous of Sphingosine-1-phosphate (S1P),
and it targets all S1P receptors (S1P1–5) with the exception
of S1P2 [3,4]. The main and well-characterized action of
FTY720 is the sequestration of circulating mature lym-
phocytes to secondary lymphoid organs via modulation of
S1P1 receptors [4,5]. The consequent important immuno-
suppressive function gave positive results in rodent
models of MS like experimental autoimmune encephalo-
myelitis (EAE) [3,6] and underlies its therapeutic activity
in MS. However, contributing mechanisms other thanl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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for FTY720’s effects in EAE [7-9] and in alternative MS
models that exclude the immunological compartment
[10,11]. Moreover, the high lipophilic FTY720 crosses
blood brain barrier (BBB) and accumulates in the brain
and spinal cord [12], and endogenous SphK2 [13] and all
the S1P receptors, with the exception of S1P4, are abun-
dantly expressed in the brain [14], further suggesting that
action of FTY720 might involve direct effects in the cen-
tral nervous system (CNS) and implying a therapeutic po-
tential of FTY720 also in other neuropathologies.
FTY720 has a potent anti-inflammatory effect in ani-
mal models of CNS injury, such as brain ischemia
[15-17], intracerebral haemorrhage [18,19], spinal cord
injury [20], Alzheimer’s disease [21-24], glioblastoma
[25] and epilepsy [26]. In vitro studies confirm direct ac-
tion of FTY720 on microglial cells, reducing the produc-
tion of pro-inflammatory cytokines from LPS-stimulated
microglia [27] or in a model of transient demyelination
in rat CNS reaggregate spheroid cell culture [28]. Not-
ably, FTY720 also enhanced the production of neuro-
trophic factors, brain-derived nerve factor (BDNF) and
glial-derived nerve factor (GDNF) by LPS-activated
microglia, [27], suggesting a FTY720-mediated shift to-
wards a neuroprotective microglial phenotype. How-
ever, a direct action of FTY720 on neurons remains
unclear. Recent studies demonstrate that, in cultured
neurons, FTY720 counteracts N-methyl-D-aspartic
acid (NMDA) or oligomeric amyloid β (Aβ)-induced
neuronal death [21,29,30] increasing the neuronal
production of BDNF [21,29].
A very useful tool to study neuronal death and neuro-
inflammation in vivo is the administration of kainic acid
(KA) in rodents: this is a well-established model of exci-
totoxicity and seizure-related neurological diseases, since
it induces seizures in animals, followed by an acute neu-
rodegeneration confined in specific regions of the brain,
the most vulnerable being the hippocampus [31,32]. KA-
induced damage is accompanied by inflammatory re-
sponses, a very common feature of neurodegenerative
diseases, driven initially by microglial cells and astrocytes,
and producing nitric oxide and pro-inflammatory cyto-
kines which ultimately exacerbate neuronal injury and
contribute to the expansion of brain damage [33-35].
Given the not fully understood action of FTY720 in
brain injury, in this study we investigated how this drug
might confer neuroprotection after excitotoxicity in vitro
and in vivo. We demonstrate that daily treatment with
FTY720 results in a reduction of neuronal loss in CA3
regions of the hippocampus after intracerebroventricular
(icv) injection of KA and in a pronounced decrease of
activated microglia at the site of injury. In addition, our
in vitro results indicate that FTY720 modulates inflam-
matory phenotype of LPS-activated microglial cells andprotects neuronal cortical cultures from NMDA-excito-
toxicity, further supporting a direct action of FTY720 as





diol) and FTY720-P (2-amino-2[2-(4-octylphenyl)ethyl]-
1,3-propanediol, mono dihydrogen phosphate ester) were
provided by Novartis. For in vitro experiments, powdered
FTY720 and FTY720-P were reconstituted in dimethyl
sulfoxide hydrochloric acid (DMSO)/50 mM HCl; for the
intraperitoneal (ip) and icv injections, FTY720 was diluted
in vehicle (saline solution). For the ip injection, FTY720
was freshly prepared every day. KA was from Abcam
(Cambridge, USA); MK801 was from Tocris (Bristol, UK).
NMDA, propidium iodide (PI) and LPS (Escherichia coli
O11:B4) were from Sigma-Aldrich (St. Louis, USA). All
cell culture supplies, if not otherwise indicated, were pur-
chased from Gibco (Life Technologies, Madrid, Spain).
Cytotoxicity 96 colorimetric assay for the quantification of
lactate dehydrogenase (LDH) release was purchased from
Promega Corporation (Madison, USA).
Animals
All procedures and experiments involving animals and
their care were carried out according to the guidelines of
the European Union Council (Directive 2010/63/EU)
and Spanish regulations (Real Decreto 53/2013) on ani-
mal ethics and welfare, and under the supervision and
with the approval of our internal animal ethics commit-
tee (University of the Basque Country, UPV/EHU). All
possible efforts were made to minimize animal suffering
and the number of animals used.
Neuronal primary cultures
Cortical neurons were obtained from the cortical lobes
of E18 Sprague–Dawley rat embryos as previously de-
scribed [36]. Briefly, neurons were resuspended in Neu-
robasal-B27 medium plus 10% fetal bovine serum and
then seeded onto poly-L-ornithine (Sigma) coated 48-
well plates at 1.5 × 105 cells per well. The medium was
replaced by serum-free Neurobasal-B27 medium 24 h
later. The cultures were essentially free of astrocytes and
microglia and were maintained at 37°C and 5% CO2.
Cultures were used at 9 to 11 days in vitro (DIV).
Organotypic cultures
Organotypic cerebrocortical cultures were obtained from
brains of 7-day-old Sprague–Dawley rat pups using the
method described by Plenz and Kitai [37] with minor
modifications [38]. Briefly, brains were removed and the
two hemispheres separated in Hank’s balanced salt
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Ca2+ and Mg2+. The thalamus and midbrain were dis-
carded, and each hemisphere was sliced with a McIll-
wain tissue chopper (Mickle Laboratory Engineering
Co., Surrey, UK) in order to obtain coronal slices of
400 μm of thickness. Slices containing cortex and stri-
atum (but not hippocampus) were selected under a
microscope and dissected to eliminate the corpus callo-
sum. Slices were plated onto Millicell CM culture in-
serts (Millipore, Madrid, Spain) and maintained in 50%
Neurobasal-B27, 25% inactivated horse serum, 25%
HBSS, 5.5 mM glucose, 2 mM L-glutamine, Antibiotic-
Antimycotic 1X (100 U/ml penicillin, 100 μg/ml
streptomycin and 0.25 μg/ml amphotericin B), at 37°C
and 5% CO2. Slices were used after 11 to 13 DIV.
Microglial cells cultures
Rat primary microglia cultures were prepared from the
cerebral cortex of newborn (P0-P2) Sprague–Dawley
rats. Briefly, cortices were dissociated and plated with
serum-supplemented Iscove’s modified Dulbecco’s
medium. After 2 weeks, confluent monolayer of cultured
astrocytes was depleted from microglia by mechanical
shaking, according to standard protocols. Free-floating
microglia were collected from shaken astrocyte flasks
and purified by plating on non-coated plastic Petri dishes
(Sterilin). After 48 h, non-adhered cells (progenitors cells)
were eliminated and microglial cells were re-plated on
poli-D-lysine (PDL; Sigma)-coated wells (1×105 cells per
well) in Dulbecco’s modified Eagle’s medium (DMEM) and
5% inactivated horse serum and used for the experiments
24 h after. The purity of cultured microglia was higher
than 99% under these conditions.
In vitro assays
Toxicity assays
Cortical neurons at 9 DIV were pre-treated for 24 h with
FTY720 (10 to 1,000 nM) and then exposed to NMDA
(25 and 100 μM) for additional 24 h in the same condi-
tioned medium. Neuronal death was estimated by meas-
uring the level of LDH released from damaged cells into
the culture media. All experiments were performed at
least in duplicate, and the values provided are the nor-
malized mean ± SEM of at least four independent
experiments.
For organotypic culture toxicity experiments, slices (11
DIV) were treated with NMDA 50 μM in HBSS (free of
Ca2+ and Mg2+) containing 2.6 mM CaCl2, 4.5 mM glu-
cose and 10 μM glycine for 30 min at 37°C, in the pres-
ence or in the absence of FTY720 (10 and 100 nM) or
MK801 (50 μM, 10 min pre-incubation), as indicated. In
addition, FTY720, when applied, was added 24 h before
and 24 h after the treatment with NMDA. Twenty-four
hours after stimulation with NMDA, the damagedregion within the slice was determined by PI uptake,
whose signal correlates with LDH release in models of
excitotoxicity [39]. Briefly, slices were incubated in PI-
containing medium (10 μM) for 1 h at 37°C and then
washed out three times with culture medium. Fluorescence
from dead cells, which take up the dye in the nucleus, was
visualized and photographed using a fluorescence micro-
scope Nikon AZ100. The captured images were analysed
by ImageJ software (http://rsbweb.nih.gov/ij/download.
html) to measure fluorescence intensity, representing PI
uptake. For each image, the corrected total fluorescence
(CTF) in the cerebral cortex was calculated in relation to
the total cortical area in each slice using the formula:
CTF ¼ Integrated density
− ðSelected area  Mean fluorescence of
background readingsÞ
Mean fluorescence of background was recorded from
randomly selected square areas outside of the area of
interest. Data, expressed as normalized mean ± SEM,
were averaged from two similarly treated slices and at
least four independent experiments run for each condition.
For the in vitro assays, the concentrations range (10 to
100 to 1,000 nM) was chosen in agreement with previ-
ous studies demonstrating efficacy of FTY720 and
FTY720-P at nanomolar levels [14,29].
Western blotting
For Western blotting assays, microglia cells on PDL-
coated wells were stimulated in DMEM serum-free
medium with LPS 100 ng/ml for the indicated time
(time-course); in another set of experiments, microglia
were pre-treated with FTY720 or FTY720-P (100 nM)
for 24 h, and later stimulated in DMEM serum-free
medium with LPS 100 ng/ml for 60 min, in the presence
or in the absence of FTY720. After washing with ice-
cold phosphate buffered saline (PBS), total protein was
extracted from microglia cell cultures by scraping the
cells in SDS/sample buffer. Samples were boiled for 10
min, separated by electrophoresis using Criterion TGX
Precast 12% gels and transferred to Trans-Blot Turbo
Midi PVDF Transfer Packs (Bio-Rad, Hercules, USA).
For immunoblotting, membranes were blocked in 5%
skimmed milk, 5% serum in tris-buffered saline/0.05%
Tween-20 (TBS-T) and proteins detected by specific
primary antibodies in 5% bovine serum albumin (BSA)
in TBS-T overnight at + 4°C (all from Cell Signalling,
Beverly, USA): phospho-p38 mitogen-activated protein
kinase (MAPK) (#9211; 1:1,000); Phospho-SAPK/JNK
(#9251; 1:1,000); total p38 MAPK (#9212; 1:1,000); total
SAPK/JNK (#9252; 1:2,000). After washing, the mem-
branes were incubated with horseradish peroxidase-
conjugated secondary antibodies (1:2,000, Sigma) in 5%
skimmed milk and 1% normal serum in TBS-T for 1 h
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chemiluminiscence according to the manufacturer’s in-
structions (Super Signal West Dura or Femto, Pierce,
Life Technologies, Madrid, Spain). Images were ac-
quired with a ChemiDoc MP system (Bio-Rad) and
quantified using Image Lab Software; values of phos-
phorylated protein were normalized to corresponding
total protein signal and provided as the mean ± SEM of
at least three independent experiments.In vivo model of neurodegeneration
We used a total of 37 adult male Sprague–Dawley rats
(200 to 250 g), divided in six independent sets of ex-
periments. Rats were kept on a 12/12 h light/dark
cycle with constant ambient temperature and humid-
ity. Food and water were available ad libitum. We
used unilateral icv injection of KA as a model of neu-
rodegeneration. Rats (n ≥ 3 per experimental group)
were anesthetized by ip of ketamine 80 mg/kg (Imal-
gene®, Merial Laboratorios Sa, Barcelona, Spain) and
xylazine 10 mg/kg (Rompun®, Bayer Hispania, S.L.,
Barcelona, Spain ) and placed into a stereotaxic appar-
atus (David Kopf Instruments, Los Angeles, USA). KA
(0.5 μg in 2 μl in saline), alone or in combination with
FTY720 (1 μg in 2 μl in saline) was injected into the
right lateral ventricle (right side referred thereafter as
ipsilateral), at the following coordinates from bregma:
−1 mm anterioposterior, 2 mm mediolateral, 4 mm
dorsoventral [40]. Injections were carried out over a 5-
min period using an infusion pump (KD Scientific,
Holliston, USA), with a constant infusion rate of 0.4
μl/min. Initially, we tested a single dose of FTY720 icv
co-injected with KA. In a second set of experiments,
we injected FTY720 together with KA, both icv, plus a
prophylactic FTY720 injection (1 mg/kg; ip) 24 h be-
fore, and subsequent daily ip injections of vehicle or
FTY720 until sacrifice 3 days after KA application.
Control animals received vehicle only. The dose of 1
mg/kg was previously reported as effective in reducing
neuroinflammation in rodent ischemic models [15,16]
and in lithium-pilocarpine-induced status epilepticus
[26]. Following surgery, three animals were housed per
cage and observed for spontaneous seizure activity
every 30 min for a total time of 120 min. Seizures were
quantitatively scored as previously described, accord-
ing to a modified Racine scale [41]: 0, normal; 1,
immobilization; 2, forelimb and/or tail extension, rigid
posture; 3, repetitive movements, head bobbing and
gnawing; 4, rearing and falling; 5, continuous rearing
and falling; 6, severe tonic-clonic seizure with loss of
postural control and 7, death in the first 2 h. Seizure
scoring was carried out blinded to the treatment re-
ceived by the animals.Histology
After 72 h of icv injection, the animals were deeply
anesthetized with chloral hydrate 400 mg/kg (Panreac
Quimica, Barcelona, Spain) and transcardially perfused
with 4% paraformaldehyde in 0.1 M PBS (pH 7.4). The
brains were removed and immediately post-fixed in the
same solution for 3 h. Then, they were washed and
stored at + 4°C in PBS/Azide (0.02%) until sectioning.
For all brains, six series of 40-μm-thick coronal sec-
tions at the level of the hippocampus were cut on a
vibratome (HM 650 V, Microm International, Walldorf,
Germany). One of the series was used for Nissl stain
(toluidine blue, Sigma-Aldrich) to evaluate the lesion
extent in the hippocampus; another series was proc-
essed with Fluoro-Jade C (FJC, Millipore), a specific
marker for degenerating neurons [42]; the remaining
sections were used for immunohistochemistry, as de-
scribed below.Quantification of the lesion size
Serial sections were stained with 1% toluidine blue solu-
tion (Nissl’s stain) to quantify lesion area in the hippo-
campus. A total of eight slices at the level of dorsal
hippocampus was used per animal. The edge of the le-
sion, restricted to the CA3 region of the hippocampus,
was determined by the border between the healthy and
the pyknotic neurons. Images of stained ipsilateral
hippocampus were acquired using Zeiss Axioplan 2
microscope coupled to an Axiocam MRc5 digital camera
(Zeiss, Oberkochen, Germany) under a 4× objective.
Microsoft Image Composite Editor Software (Microsoft
Research) was used to reconstruct the entire hippocam-
pus; then CA3 and hippocampal areas (mm2), referring
to Paxinos and Watson rat atlas [40], and lesion area
were measured for each slice using ImageJ software.
Mean lesion area per animal was calculated and normal-
ized to hippocampus mean area or CA3 mean area.
Similarly, adjacent set of sections were used for FJC
staining to detect dying neurons, as previously described
[42]. Briefly, floating sections were mounted on gelatin-
coated slides and dried at room temperature overnight.
Sections were then rehydrated by sequential soaking in
100% ethanol (3 min), 70% ethanol (3 min) and distilled
water (two times for 2 min). After 15 min incubation in
0.06% potassium permanganate, sections were rinsed for
1 min in distilled water and immersed in a solution con-
taining 0.0001% solution of FJC dissolved in 0.1% acetic
acid vehicle for 20 min. The slides were then rinsed
through distilled water (three times for 1 min) and air
dried room temperature overnight. The air dried slides
were cleared in xylene (two times for 3 min) and then
coverslipped with DPX non-fluorescent mounting media
(Sigma). Sections were examined with a Zeiss Axioplan
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MRc5 digital camera (Zeiss).
Immunohistochemistry
Immunoperoxidase staining on free-floating sections
was used for identification of neurons and microglial
cells. Briefly, after quenching of endogenous peroxidase
(H2O2 0.3%) and blocking nonspecific binding with 4%
normal goat serum, 0.1% Triton X-100 in PBS, we used
the following primary antibodies: anti-neuronal nuclei
(NeuN) (#ABN78, Millipore; 1:1,000); anti-ionized
calcium-binding adapter molecule1 (Iba1) (#019-19741,
Wako; 1:1,000). Subsequently, primary antibodies were
detected using appropriated biotinylated secondary anti-
bodies (1:200; Vector Laboratories, Burlingame, USA),
followed by incubation with avidin-biotin-peroxidase
complex (Vector Laboratories). Peroxidase activity was
visualized by incubation in 3,3′-diaminobenzidine (DAB)
substrate (Roche, Basel, Switzerland). Finally, the sec-
tions were mounted in gelatin-coated slides, dehydrated
through graded alcohols, cleared with xylene and cover-
slipped with DPX. The sections were visualized using
Zeiss Axioplan2 microscope coupled to an Axiocam
MRc5 digital camera (Zeiss) to examine neuronal integ-
rity and the extent of microgliosis, and representative
photomicrographs of ipsilateral CA3 regions were taken
under a 10× magnification objective. The extent of
microgliosis was quantified by counting the number of
Iba1+ cells in the ipsilateral CA3 hippocampus in three
independent sections per animal, using three 40×−fields
per section. Negative controls in all experiments in-
cluded the omission of one of the primary antibodies
and provided no labelling, indicating the reliability and
specificity of the immunostaining.
Statistical analysis
Data are expressed as mean ± SEM. Statistical analyses
were performed using Prism version 4.0 (GraphPad Soft-
ware, USA). Comparisons between two groups were ana-
lysed using unpaired,two-tailed Student’s t test or
Mann–Whitney non-parametric test. Comparisons
among multiple groups were analysed by one-way or
two-way analysis of variance (ANOVA), as appropriate,
followed by Bonferroni post hoc test. P ≤ 0.05 or P ≤ 0.01
was defined as significant or highly significant, respectively.
Results
FTY720 reduces excitotoxic neuronal death in vitro
For the induction of excitotoxic neuronal death, we used
primary neuronal cultures and organotypic cortical cul-
tures, two experimental settings that exclude confound-
ing interactions of the peripheral immune system. Initial
experiments with FTY720 alone showed that it was
somewhat toxic, albeit not significant, at the highestconcentration used (1,000 nM), an effect which could be
due to receptor-independent mechanisms [43]. Subse-
quently, neuronal cultures were subjected to excitotoxic
concentration of NMDA (25 and 100 μM), and neuronal
death was assessed 24 h later measuring LDH released
from damaged neurons in the medium. NMDA caused
neuronal death in a concentration-dependent fashion.
FTY720 (10 to 1,000 nM), applied to the cultures 24 h
before NMDA and maintained in the medium thereafter,
reduced LDH release and, therefore, neuronal damage,
with higher dose being less effective if not slightly toxic
(Figure 1A). This protective effect was also maintained
at the higher concentration of NMDA.
To further assess the neuroprotective action of
FTY720 against NMDA-excitotoxicity, we used cerebro-
cortical organotypic slices, a more integral ex vivo prep-
aration that maintains many aspects of in vivo biology,
including preserved brain architecture and cellular com-
ponents representation. Moreover, organotypic cortical
slices are vulnerable to NMDA receptor activation [36].
Cortical slices were pre-treated with FTY720 (10 and
100 nM) for 24 h and then incubated with NMDA (50
μM) for 30 min. Organotypic cultures were then washed
out and maintained in culture medium for additional 24
h, in the presence or in the absence of FTY720, as indi-
cated (Figure 1B). PI uptake was used to quantify
NMDA-induced cell death, and fluorescence intensity
was expressed as CTF referred to NMDA treatment as
100% (Figure 1B). NMDA treatment significantly in-
creased the PI uptake as compared to control, an effect
that was reduced by low concentrations of FTY720
(Figure 1B, C), in line with the results obtained in pri-
mary cultures. The NMDA receptor antagonist MK-801
was fully protective (Figure 1B).
Prolonged treatment with FTY720 reduces hippocampal
degeneration caused by icv injection of KA
The results obtained in vitro attest the neuroprotective
capacity of FTY720 against excitotoxic neuronal death.
To further evaluate this feature, we tested FTY720
effects in vivo, in a model of neurodegeneration in rats
using icv injection of KA. This potent excitotoxin
induces cell death of selected populations of neurons in
the hippocampus of treated animals, the most relevant
being CA3 region. KA (0.5 μg/2 μl) was injected in the
right lateral ventricle, and neuronal damage was evalu-
ated 3 days later using Nissl’s and FJC staining, and
immunohistochemistry with anti-NeuN antibody. In a
first set of experiments, we applied a single dose of
FTY720, icv (1 μg/2 μl) together with KA (Figure 2A)
and found no significant differences between KA- and
KA+FTY720-treated animals, neither in seizure-like
score (Figure 2B) or in neuronal death in CA3 region, as
assessed by quantification of Nissl’s stained sections
Figure 1 FTY720 prevents excitotoxic neuronal death in cerebrocortical primary and organotypic cultures. (A) Neuronal primary cultures 9 DIV
were pre-treated with increased concentration of FTY720 (10 to 1,000 nM) for 24 h and then stimulated with N-methyl-D-aspartic acid (NMDA)
(25 to 100 μM) in the same conditioned medium. After 24 h of NMDA treatment, lactate dehydrogenase (LDH) released in the medium was
measured and mean ± SEM were reported as per cent of non-treated neurons (n = 6, except for FTY720 1 μM, n = 2; two-way ANOVA: * or
#P < 0.05; ** or ##P < 0.01; # vs control). (B) Organotypic cultures were pre-treated 24 h with FTY720 (10 and 100 nM) and then incubated
with NMDA (50 μM) for 30 min, in the presence or in the absence of FTY720 or MK801 (50 μM, 10 min pre-incubation). FTY720 was added for
additional 24 h. The damage was detected by PI uptake 24 h after treatment with NMDA and propidium iodide (PI) intensity was measured
as corrected total fluorescence (CTF). Data are expressed as the mean ± SEM (n ≥ 4 independent experiments; in each experiment, at least
two slices for condition were used) and referred to percent of NMDA-treated neurons (dotted line). Student’s t test: *P < 0.05 and **P < 0.01
vs NMDA-treated cells. (C) Representative photographs showing PI uptake in cortical slices treated as in (B). Scale bar: 1 mm.
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chronic treatment with FTY720, more similar to the
in vitro approach. Specifically, in addition to the previ-
ously described icv injection, rats in the KA+FTY720
experimental group were treated with a prophylactic ip
injection of FTY720 (1 mg/kg) followed by daily ip in-
jections of FTY720 (1 mg/kg) until sacrifice (Figure 3A).
Behavioural observation after treatment with KA re-
vealed that FTY720 slightly ameliorated the symptoms
(Figure 3B) and reduced neuronal degeneration as well
as the extent of the lesion in CA3 hippocampal region
(Figure 4A,B). Indeed, quantification of the damaged
area showed a significant reduction in KA+FTY720-
treated animals as compared to their KA-treated coun-
terparts (Figure 3C,D), indicating a neuroprotective
action of FTY720 against KA-induced neurodegenera-
tion in vivo. Histological analysis further confirmed the
protective effects of FTY720 as the number of FJC+
degenerating neurons was lower in the CA3 region of
KA+FTY720-treated animals as compared to KA only
group (Figure 4C). Moreover, the KA-treated group had
significantly lower amount of NeuN+ cells in CA3 than
KA+FTY720-treated animals (Figure 4D).FTY720 reduces activation of microglial cells following
KA-induced hippocampal neuronal death
In order to evaluate of FTY720 on the pro-inflammatory
milieu associated with KA-induced seizure-like behav-
iour and hippocampal degeneration, we focused our at-
tention on the main effectors of neuroinflammation in
the brain, namely microglial cells. At 3 days post icv of
KA, reactive microglia showed large somata and thick
primary processes localized in the hippocampus at the
site of injury, as revealed by Iba1 immunostaining
(Figure 5A). In vehicle-treated rats, microglia were
uniformly distributed throughout the hippocampus
and presented a less reactive phenotype, with fine and
extended processes and small cell bodies (Figure 5C).
The number of Iba1+ cells in ipsilateral CA3 was
counted, and the corresponding graph (Figure 5D)
shows a significantly lower number of Iba1+ cells in
CA3 of the KA + FTY720 group (Figure 5B) than in
CA3 of KA group (Figure 5A).
FTY720 modulates microglia responses in vitro
MAPKs signalling is one of the most important path-
ways involved in microglia-mediated inflammatory
Figure 2 Single acute treatment with FTY720 does not protect from kainic acid (KA)-induced neurodegeneration in vivo. (A) Schematic timeline of
experimental protocol. FTY720 was applied as a single icv dose together with KA. Seizure score was evaluated at the end of the surgery observing the
animals during 30 min intervals over a period of 2 h. Animals were sacrificed 3 days after icv injection and brain tissues processed for immunohistochemical
analysis. (B) Effect of FTY720 (1 μg/2 μl, icv) on seizure-like behaviour induced by KA icv injection (0.5 μg/2 μl). Seizure was scored as described in the
‘Methods’ section, with the higher score indicating greater seizure severity. The mean seizure score for KA group (n = 6) and KA + FTY720 group (n = 6)
was plotted against time after icv. (C, D) Quantification of the extent of the lesion in animal icv injected with KA (n = 6) and KA + FTY720 (n = 6) after
Nissl’s staining. Eight slices per animal were evaluated. Area of the lesion and areas of CA3 and hippocampus were measured for each slice (mm2) in the
ipsilateral side. The mean lesion area per animal was calculated and normalized to the mean CA3 or hippocampal areas (C, D). Data are expressed as the
mean ± SEM of n = 6 animals for each experimental group (two independent experiments with 3 animals in each group). There is no significant difference
between the two groups (B: Mann–Whitney test at any time point of recorded seizure score; C and D: Student’s t test).
Figure 3 Repeated (daily) treatment with FTY720 protects from kainic acid (KA)-induced neurodegeneration in vivo. (A) Schematic timeline of
experimental protocol. FTY720 or vehicle was ip injected (1 mg/kg) daily, starting 1 day before icv surgery up to 2 days thereafter. Animals
received a single icv injection of KA alone (0.5 μg/2 μl) or in combination with FTY720 (1 μg/2 μl). Seizure score was evaluated post-surgery at
30-min intervals over a period of 2 h. On day 3 after icv injection, animals were sacrificed and brain tissues processed for immunohistochemical
analysis. (B) Effect of daily FTY720 treatment on seizure-like behaviour induced by KA icv injection. Seizure was scored as described in the
‘Methods’ section, with the higher score indicating greater seizure severity. The mean seizure score for KA group (n = 12, four independent
experiments with 3 animals each) and KA + FTY720 group (n = 13, four independent experiments with ≥3 animals each) was plotted against
time after icv. *P < 0.05 vs KA-treated group, Mann–Whitney test at any time point of recorded seizure score. (C, D) Quantification of the extent
of the lesion in animal icv injected with KA (n = 11) and KA + FTY720 (n = 12) after Nissl’s staining. Eight slices per animal were evaluated. Area of
the lesion and areas of CA3 and hippocampus were measured for each slice (mm2) in the ipsilateral side. The mean lesion area per animal was
calculated and normalized to the mean CA3 or hippocampal areas (C, D). Only ipsilateral hemisphere was considered for the analysis. *P < 0.05
and **P < 0.01 vs KA-treated group, Student’s t test. All data are expressed as the mean ± SEM of n ≥ 11 animals for each experimental group
(four independent experiments).
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Figure 4 Histological analysis of the protective effect of FTY720 in CA3 region following icv injection of kainic acid (KA). Slices collected 3 days
after icv surgery were stained with Nissl (A, B), Fluoro-Jade C (FJC) (C), and anti-NeuN antibody (D). Figure shows representative photomicrographs of
bright field (A, B, D) and epifluorescence (C) microscopy images obtained from coronal sections of KA-treated (left panel) and KA + FTY720-treated
animal groups (right panel). Only the damaged ipsilateral hemisphere is shown. KA-induced cell death is evident in the CA3 region, as indicated by
Nissl’s staining (A, B), lower number of NeuN+ cells (D), and increased density of FJC+ neurons (C). KA + FTY720-treated group (right panel) shows
significant attenuated loss of neurons as compared to KA-treated group (left panel). (A) Dorsal ipsilateral hippocampus. Scale bar: 1 mm. (B-D) CA3
region of ipsilateral hippocampus. Scale bar 500 μm.
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anisms by which FTY720 influence microglia activity, we
studied the effects of FTY720 in LPS-induced activation
of MAPKs pathways in primary microglia (Figure 6 and
Additional file 1: Figure S1). LPS (100 ng/ml) led to acti-
vation of JNK and p38 which peaked at around 60 min
of stimulation (Figure 6A, B). Pre-treatment of cells with
FTY720 or FTY720-P (100nM, similar to what was used
previously, [27]) resulted in a significant reduction of
LPS-dependent phosphorylation of p38 (Figure 6D),
while no changes were observed in the phosphorylationof JNK (Figure 6C), indicating a specific action of
FTY720 in modulating microglia responses associated
with p38 activation.
Discussion
In the present study, we describe the neuroprotective ac-
tion of FTY720, the first oral treatment approved for
relapsing-remitting MS, using in vitro and in vivo
models of excitotoxic neuronal death which are relevant
to acute CNS injury (for example, cerebral ischemia,
traumatic brain injury) and chronic neurodegenerative
Figure 5 FTY720 reduces microgliosis in CA3 region after icv injection of kainic acid (KA). Representative photomicrographs of ipsilateral hippocampal
coronal sections of KA-treated (A), KA + FTY720-treated (B) and control (C) animal groups, immunostained with anti-Iba1 antibody (bright field
microscopy). Images on the top of each panel are low magnification photomicrographs showing the entire ipsilateral dorsal hippocampus (scale bar 1
mm). The black frame represents the size field used for counting Iba1+ microglial cells in the CA3 region. Images on the bottom of each panel illustrate the
area used for microglial cell counting (scale bar 100 μm). (D) Quantification of the number of Iba1+ microglial cells at CA3 region in control, KA-treated and
KA + FTY720-treated animals. Three fields per slice were used to cover the CA3 region and to count the Iba1+ microglial cells at the site of injury, and a
total of three slices per animal were analysed. Data are expressed as the mean ± SEM of positive cells in ipsilateral CA3 region per slice (control: n = 2; KA
and KA + FTY720 n = 9 from three independent sets of experiments). Student’s t test: *P < 0.05 and **P < 0.01 vs control; #P < 0.05 vs KA.
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sclerosis, multiple sclerosis, and others) [46].
Despite the emerging role of FTY720 as an effective
agent reducing neurodegeneration and promoting repara-
tive mechanisms in different neurological diseases, little is
known about the mechanism of action and cellular targets
in the brain. Non-immunological, anti-inflammatory ac-
tions S1PRs-mediated on glial cells have been associated to
the beneficial effects of FTY720 [15,26,47,48]. Conversely,a direct neuroprotective effect on neurons is highly de-
bated, although neurons express S1PRs [12,14,49] and thus
may be primarily influenced by FTY720, but the issue is
still unclear. Previous studies reported a lack of direct pro-
tection of FTY720-P in vitro, in cortical primary neurons
against glutamate excitotoxicity or oxidative stress-induced
cell death [15], or in hippocampal neuronal cell cultures
subjected to hypoxia [16]. Conversely, we observed in our
in vitro models (that is, cortical primary and organotypic
Figure 6 FTY720 modulates inflammatory responses of lipopolysaccharide (LPS)-activated microglia. Microglial cells treated with LPS (100 ng/ml,
DMEM without serum) showed time-dependent phosphorylation of JNK (A) and p38 (B) MAPKs, as determined by Western blot analysis. (C)
Pre-treatment for 24 h with FTY720 or FY720-P did not reduce LPS-induced phosphorylation of JNK at 60 min, while a significantly effect was
shown on LPS-induced p38 activation at the same time point (D). Levels of phosphorylated target protein were normalized to the expression
of the corresponding non-phosphorylated form and expressed as percent of untreated cells. The insets on the top of each graph show
corresponding, representative Western blots. Lanes have been cropped from the original gel, and minimal adjustments were made to the
brightness and contrast settings to improve the clarity of the figure. All lanes shown are from the same gel. Original uncropped blots are
shown in Additional file 1: Figure S1. Values are given as mean ± SEM, n ≥ 3. Statistical analysis: A and B, one-way ANOVA, *P < 0.05 or
**P < 0.01 vs untreated cells; C and D, two-tailed t test, *P < 0.05 or **P < 0.01 vs internal control without LPS.
Cipriani et al. Journal of Neuroinflammation  (2015) 12:86 Page 10 of 14cultures) a neuroprotective effect of FTY720 against exci-
totoxic concentrations of NMDA. Both the in vitro models
we used for testing the effect of FTY720 exclude the com-
ponent of the peripheral immune system, thus providing
evidence of an action of the drug on neurons, independent
of its immunomodulatory function. We chose non-
phosphorylated FTY720 relying on previous studies reveal-
ing its efficacy in neuronal and oligodendrocyte progenitor
cell cultures [30,50]. Moreover, Sphk2 is the predominant
S1P-synthesizing isoform expressed in brain tissues [51,52],and a recent work showed how FTY720 was rapidly taken
up by human SH-SY5Y neuroblastoma cells and FTY720-
P was generated in the nucleus by SphK2 [52], implying
that phosphorylation of FTY720 may occur also in our
neuronal and organotypic cultures. We showed that
FTY720, although exogenously applied in the non-
phosphorylated form, reduced neuronal death induced
with NMDA, but the effect occurred only in case of pro-
longed treatment, pre- and post-NMDA. In turn, as shown
in Figure 1A, the highest dose of FTY720 (1,000 nM) is
Cipriani et al. Journal of Neuroinflammation  (2015) 12:86 Page 11 of 14toxic in our experimental conditions, an effect that may be
due to receptor-independent mechanisms, as previously re-
ported [43].
We obtained similar protective results in cortical orga-
notypic cultures subjected to excitotoxicity. However, in
organotypic cultures the higher dose of FTY720 (100
nM) failed to reduce neuronal death, while it still main-
tained effectiveness on primary cultures. It should be
stressed, in this case, the greater complexity of organoty-
pic cultures compared to primary neuronal cultures, the
former preserving cytoarchitecture, cellular composition
and cell-cell interactions of the source brain region
[37,38]. Moreover, organotypic cultures derive from
post-natal brains, while neuronal cultures are from em-
bryonic brains, and more mature neurons can present
different responses to a same stimulus compared to em-
bryo-derived neurons. Therefore, mechanisms other than
those taking place in primary cultures may contribute to
or interfere with FTY720-induced neuroprotection, in
particular those arising from neuron-glia interactions in
organotypic cultures. However, the use of the organotypic
culture tool and the effectiveness, albeit weak, of FTY720
also in this experimental model may be very useful for fur-
ther screening and characterization of protection mecha-
nisms recruited by this drug, without requiring whole
animal studies.
Our in vitro findings are consistent with recent studies
showing a direct, S1P1R-mediated, neuroprotective ac-
tion of FTY720-P [29,30] and non-phosphorylated
FTY720 [30] in primary cortical cultures subjected to
NMDA excitotoxicity [29]. Pre-treatment appears critical
for non-phosphorylated FTY720 efficacy and may par-
tially explain opposite results obtaining in other in vitro
studies [15]. Thus, Di Menna et al. showed that non-
phosphorylated FTY720, which presented neuroprotec-
tive effects similar to FTY720-P in their experiments,
lost its protective activity when applied during or after
excitotoxic insult, whereas FTY720-P kept it [30]. Pre-
treatment could be necessary to allow intracellular
phosphorylation of FTY720 and transport of FTY720-P
outside the cells leading to the activation of S1PRs that
directly promote neuroprotection or can result in
accumulation of other mediators of neuroprotection
that in turn would counteract NMDA-induced toxicity.
Supporting the last hypothesis, pre-treatment with
FTY720-P increases BDNF levels in neurons and medi-
ates neuroprotection in a BDNF-dependent manner
[29]. Recent findings suggest a fundamental and more
general role of BDNF release in FTY720-mediated neu-
roprotection. Firstly, FTY720-P-driven up-regulation of
neuronal BDNF attenuated oligomeric Aβ-induced
neurotoxicity in primary mouse cortical neurons [21].
Secondly, FTY720 restored normal BDNF expression
levels in the brain in a mouse model of Rett syndrome[29] and in mice injected with Aβ [23], ameliorating
locomotor and cognitive functions, respectively.
Together, our data further support the hypothesis of
direct neuroprotective properties of FTY720 in neurons
and contribute to clarify the effective conditions against
NMDA-mediated excitotoxicity, in terms of concentra-
tions and importance of the pre-treatment.the overall
neuroprotective effect of FTY720, in particular when the
complexity of the experimental models augments, as in
the case of organotypic cultures and in vivo model (see
Discussion below).
We further assessed in vivo the results obtained
in vitro, using unilateral icv injection of KA as a model
of excitotoxicity able to induce a pronounced neuronal
death in hippocampus, particularly in ipsilateral CA3.
Inflammatory processes also contribute to neuronal
damage [33,34] allowing to study both the effect of
FTY720 on neuronal death and on neuroinflammation.
We found that a prophylactic dose followed by daily
treatment with FTY720 for 3 days significantly decreased
KA-induced hippocampal degeneration. However, pro-
tection in these experimental conditions was not
achieved with a single dose of FTY720, which is consist-
ent with our in vitro assays in cortical neurons as well as
with findings in other animal models of degenerating
diseases [8,10,19]. In addition, despite the observed re-
duction of neuronal death with FTY720, seizure-like be-
haviour improved modestly in line with previous
observations [53]. To our knowledge, this is the first
demonstration of a neuroprotective action of FTY720
against KA-induced hippocampal neurodegeneration
and, together with its beneficial role in a model of lith-
ium/pilocarpine-induced status epilepticus in rats [26],
reveals that FTY720 is a potential novel drug in the
treatment of epilepsy.
Accumulation of microglia at the site of injury oc-
curs in response to KA-induced neuronal degener-
ation [33,35] and may contribute to neuronal damage
by producing pro-inflammatory cytokines, free radi-
cals and enzymes that further worsen the final out-
come of injury [34,35]. Accordingly, we observed a
robust increase in the number of microglial cells with
an activated morphology at the site of injury 3 days
after KA application, which was reduced by FTY720
treatment. These findings are consistent with those
obtained in the model of lithium/pilocarpine-induced
status epilepticus in rats, where authors found reduced
neuronal loss, decreased activation of microglia and
astrocytes in the hippocampus and lower expression of
interleukin-1 β (IL-1β) and tumour necrosis factor α
(TNFα) at 4 days post-status epilepticus following
FTY720 treatment [26]. Reduced production of in-
flammatory mediators by microglia may in turn con-
tribute to the reduction of neuronal death [26]. In
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brain injury [31,32,46], and effects of FTY720 on as-
trocytes have been observed in vitro and in vivo
[26,48,54]. Therefore, astrocytes may also contribute
to FTY720-mediated neuroprotection of KA toxicity.
The fact that FTY720 reduces microgliosis and contrib-
utes to neuroprotection of KA-induced excitotoxicity
prompted us to investigate the mechanisms of FTY720 in
modulating microglial responses. Microglia are endowed
with S1P receptors, and their expression varies depending
on the activation state [12,27,55]. FTY720, via activation
of S1P1 receptors, down-regulates activated microglial
production of pro-inflammatory cytokines TNFα and IL-
1β following lysophosphatidyl choline-induced demyelin-
ation [28]. Likewise, the production of pro-inflammatory
cytokines was lowered by FTY720-P in LPS-activated pri-
mary microglial cells, while production of neurotrophic
factors BDNF and GDNF increases [27]. However, little is
known about modulation by FTY720 of intracellular sig-
nalling pathways regulating microglial transcriptional ac-
tivity and responses. MAPKs are critical intracellular
signalling pathways involved in microglial activation and
production of cytokines [44,45]. We stimulated microglial
cell cultures with the bacterial endotoxin LPS, well known
as activator through TLR4 of MAPKs pathway, and an in-
ducer of M1-like, pro-inflammatory and neurotoxic
phenotype in microglia [56]. We found that LPS treatment
induced a time-dependent activation of JNK and p38
MAPKs which is differentially affected by FTY720, lower-
ing the activation of the later while no significant effects
were observed on the JNK pathway. We obtained similar
results with FTY720-P suggesting that this form is respon-
sible for reducing activation of p38 signalling pathway.
Albeit previous reports suggested that p38 MAPK may
play a critical role in harmful microglial activation in acute
brain injury [44], in vivo relevance of the differential regula-
tion by FTY720 of p38 and JNK activation on microglial
cells needs further elucidation. We propose that FTY720
directly interferes with the neurotoxic microglia activation
profile, as demonstrated by the modulation of p38 pathway,
and it promotes a neuroprotective phenotype that ultim-
ately acts in concert with a direct neuroprotective action of
the drug on neurons. Moreover, FTY720-induced release of
neurotrophins in vivo, from neurons and/or microglia can
act as endogenous neuroprotectants and produce a micro-
environment favourable to neuroprotection and neurore-
generation. Taken together, our results provide new
evidence showing that FTY720 negatively regulates pro-in-
flammatory signalling pathways converging into p38 phos-
phorylation in microglia.
Conclusions
In summary, we provide evidence of the neuroprotective
role of FTY720 against excitotoxic neuronal death, bothin cortical neuronal and in organotypic cultures, as well
as in vivo in KA-induced hippocampal degeneration,
whereby FTY720 attenuates microgliosis. Furthermore,
we show that FTY720 modulates the microglia inflam-
matory phenotype in vitro by reducing LPS-mediated
activation of p38 MAPK signalling pathway. Thus,
FTY720 shares both direct neuroprotective and anti-in-
flammatory properties that can contribute to overall
neuroprotection. In particular, the potential of FTY720
to switch microglia phenotype from a detrimental to a
protective one represents a therapeutic mechanism for
attenuating acute and chronic CNS damage.Additional file
Additional file 1: Figure S1. Original Western blots. FTY720 modulates
cropped to generate Figure 6. Areas outlined by the red box identify the
region which was cropped for generating the insets used in Figure 6 of
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